Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15828124 | 1.00 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL15393738 | 1.00 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL430115 | 1.00 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL450251 | 1.00 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL430135 | 0.88 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL448968 | 0.88 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL446437 | 0.88 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL13497137 | 0.82 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL11539847 | 0.75 | MEN1 (0.38) | MEN1KMT2ACYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL3427906 | 0.69 | KMT2A (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-9123647-B2 | Curable composition | LG CHEM, LTD. (KR) | 2015-09-01 | — | — | US | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8981095-B2 | Intermediate compounds and process for the preparation of lurasidone and salts thereof | MAPI PHARMA LTD. (IL) | 2015-03-17 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140175333-A1 | CURABLE COMPOSITION | LG CHEM, LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | MAPI PHARMA LTD. (IL) | 2014-06-26 | — | — | US | disclosed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8524921-B2 | Liquid tetracarboxylic dianhydrides and process for the preparation thereof | HITACHI CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2429979-A1 | NOVEL HERBICIDES | Syngenta Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
| US-20120065066-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| WO-2010133232-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | WO | disclosed |
| US-7452571-B2 | Method of sealing semiconductor element mounted on gold-plated printed circuit board | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2008-11-18 | — | — | US | disclosed |
| US-20070104872-A1 | METHOD OF SEALING SEMICONDUCTOR ELEMENT MOUNTED ON GOLD-PLATED PRINTED CIRCUIT BOARD | SHIN -ETSU CHEMICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | MEN1 3981/4885KMT2A 847/4885CYP1A2 3374/4885 |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | MEN1 4045/4885KMT2A 1967/4885CYP1A2 3894/4885 |
| US-20120065066-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | MEN1 4280/4885KMT2A 674/4885CYP1A2 67/4885 |
| US-20140179922-A1 | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | REN, AVPR1B, AVPR2 | MEN1 2967/4885KMT2A 3029/4885CYP1A2 847/4885 |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | MEN1 3981/4885KMT2A 847/4885CYP1A2 3374/4885 |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | MEN1 4045/4885KMT2A 1967/4885CYP1A2 3894/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | MEN1 3682/4885KMT2A 1745/4885CYP1A2 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.